Entities

Voyager Capital is a Seattle-based venture capital firm founded in 1997, investing in early-stage business-to-business technology companies in the Pacific Northwest and Western Canada. Its current strategy focuses on AI-driven business solutions, software-enabled hardware, sustainable agriculture and supply-chain technology. It supports founders with operational experience, customer introductions and hiring advice from the first venture financing onward. Its public portfolio includes AI and deep technology companies such as 4AG Robotics, Carbon Robotics, Overland AI, Rapta, Averlon, Paxton and WellSaid Labs. Its current directory lists nine staff and venture partners and nine strategic advisers. Managing Directors Erik Benson, Diane Fraiman and Co-Founder Bill McAleer lead the firm. Voyager announced $100 million for its fifth fund in October 2019. Its March 2026 SEC adviser filing identifies Fund VI and seven other fund vehicles under numbered reporting names; disclosed asset values do not establish fundraising totals. It joined 4AG Robotics' CAD $40 million Series B announced July 2025.

Tokyo-based drug-discovery startup developing medicines based on sensory stimulation and the connection between the brain and peripheral organs. Its Sensory Medicine approach uses odor components to transmit signals to brainstem response centers through sensory and vagus nerves, with the aim of inducing protective physiological responses such as metabolic suppression, reduced inflammation and improved organ blood flow. Based on research at Kansai Medical University, the company is developing drug candidates intended to induce an artificial hibernation-like protective state for emergency medical conditions. Its research remains in early nonclinical development. Myrodia combines academic neuroscience with venture-backed drug development and pharmaceutical management expertise.

Biotechnology venture capital firm and company builder that develops early therapeutic discoveries into drug-development companies. Remiges sources intellectual property from Japanese academic institutions and biotechnology research, supports hypothesis validation and incubation, and leads early-stage financings alongside international investor syndicates. It provides scientific, clinical, business-development and board support, drawing on pharmaceutical networks and experienced company leaders to advance programs toward global development. Its portfolio includes neuroscience, optogenetic retinal gene therapy, gut-brain therapeutics, sensory medicine, oncology and other areas of biopharmaceutical innovation. The US parent works with RDiscovery, its distinct Japanese investment manager and incubator.

San Francisco Bay Area biotechnology company founded in 2018, formerly named Digestome Therapeutics, developing oral medicines that influence brain activity through the gut-brain axis. Its lead investigational drug DGX-001 acts on gut enteroendocrine cells to modulate the vagus nerve; the compound is intended to remain restricted to the gut rather than relying on systemic exposure or direct delivery to the brain. DGX-001 completed a healthy-volunteer Phase I study and the company is preparing a Phase II program for cognitive impairment across different diseases, including neurological and psychiatric conditions. Its pipeline includes neuropeptides, related peptides and small molecules for cognition, depression, anxiety and inflammatory disease. The technology is based on research by Kousaku Ohinata at Kyoto University. Clinical efficacy remains to be established.

Stefan Larson is published by Sectoral Asset Management as Venture Partner. Became Venture Partner in2024 after joining the manager as Partner in2018. Holds a Stanford biophysics PhD and earlier McGill and Toronto science degrees, with entrepreneurial and venture-investing experience.

Emmertech is a Regina-based private investment firm specializing in applied technologies for agriculture and agribusiness. It invests in early and growth-stage companies that improve agricultural productivity and yields or reduce production costs, with an international mandate and a focus on Canadian agricultural systems. Its portfolio includes autonomous harvesting and farm robotics, railcar automation, grain-quality analysis, predictive crop analytics, sensing and precision crop chemistry. The current public team comprises Managing Partner Kyle Scott, Partners Rob Russell and Erin Trapp, Partner for Growers Kristjan Hebert, and Controller Janessa Fox. Emmertech Fund 1 closed at CAD $60 million on December 31, 2021, with the final close announced January 18, 2022. Its management transitioned from Conexus Venture Capital to Emmertech Fund #1 Fund Management on February 6, 2024, while Conexus retained the general partner role. The current website operates as Emmertech Capital Partners. Its public directory lists 10 active Fund 1 portfolio companies, including 4AG Robotics, SwarmFarm Robotics, Rayhawk Technologies, Ground Truth Ag and Ukko Agro.

InBC Investment Corp. is a British Columbia Crown corporation and strategic investment fund that invests directly in innovative private companies and in venture funds with a strong connection to the province. Its mandate combines financial returns with economic, social and environmental benefits. Its investment themes explicitly include AI, robotics, quantum computing, deep technology, life sciences, maritime innovation and climate technology. The province introduced its CAD $500 million strategic investment mandate in 2021; InBC also continues legacy operations of the BC Immigrant Investment Fund and BC Renaissance Capital Fund. Its current public roster lists 20 staff, led by Interim CEO Daniel Muzyka and Chief Investment Officer Thomas Park, and eight board members chaired by Suzanne Trottier. The CIO has statutory authority for investment decisions. Its public portfolio includes Photonic, 4AG Robotics, MarineLabs, Novarc Technologies and Clarius Mobile Health, alongside investments in venture funds. InBC co-led 4AG's October 2023 preferred-share financing and participated in its July 2025 Series B.

Tokyo-based biotechnology investment manager and venture incubator within the Remiges Ventures group. It sources early therapeutic discoveries from Japanese universities, research institutions and pharmaceutical companies, validates and translates them into drug-development programs, and builds companies around the resulting intellectual property. RDiscovery combines seed and early-stage financing with in-house scientific and clinical expertise, company formation, management support, board governance and subsequent syndicated fundraising. Its RDiscovery Fund supports pre-startup translational research as well as biotechnology ventures in Japan and internationally, connecting Japanese drug-discovery assets to global development networks. The Japanese manager is RDiscovery, KK, formerly Remiges Ventures, KK; it is distinct from the US parent Remiges Ventures.

Tokyo-based clinical-stage biotechnology company founded in 2016 that develops optogenetic gene therapies to restore vision lost through retinal degeneration. Its lead candidate RV-001 uses an AAV vector to deliver a gene encoding chimeric rhodopsin, a light-sensitive protein designed to make surviving retinal interneurons respond to light after photoreceptor loss. It is administered by intravitreal injection and is being evaluated in a Phase I/II trial for retinitis pigmentosa, with an approach intended to work across different causative genetic mutations. The technology originated in joint research at Keio University School of Medicine and Nagoya Institute of Technology. Restore Vision also develops additional retinal gene-therapy programs and manufacturing capabilities; its therapies remain investigational.

Tokyo-based biotechnology company founded in April 2025 that develops medicines for peripheral neuropathy and neuropathic pain. Its lead program SNT-001 is an oral small molecule intended to relieve pain while promoting repair and regeneration of damaged peripheral nerves through a novel mechanism involving cytoskeletal factors. Target conditions include chemotherapy-induced and diabetic peripheral neuropathy and postherpetic neuralgia. SNT-001 completed Phase I testing and is being prepared for Phase II development. Originating from Toray research, the program is supported by an exclusive worldwide license. Sanodyne was formed with venture investors to develop the asset into a potential disease-modifying treatment; efficacy and regulatory approval remain to be established.

Michel Michaelides is Eye2Gene’s Chief Medical Officer and co-founder, a Moorfields consultant and UCL ophthalmology professor. He contributes inherited-retinal-disease expertise and clinical-trial leadership; academic research funding is not company financing.

Fukuoka-based Kyushu University spinout founded in 2015 that develops donor-derived NK-like immune-cell medicines for difficult-to-treat solid tumors. Its GAIA NK-like cell platform uses proprietary culture methods to produce active, tumor-infiltrating cells without genetic modification; mixed-donor manufacturing and frozen formulations are designed to provide a consistent, ready-to-use supply. Lead candidate GAIA-102, also called fulamleucel, is in clinical development for pediatric solid tumors including neuroblastoma and for gastric and pancreatic cancer with peritoneal dissemination. The company combines clinical drug development with cell-manufacturing process development, quality control and production capacity, including a cell-processing facility on the Kyushu University Hospital campus. Its products remain in development.

Business Development Division Director and Venture Capitalist at JIC VGI, joined in 2025. Previously supported startup R&D at NEDO from 2021 and worked on startup ecosystem hub selection at the Cabinet Office in 2019. Holds a master’s in technology management from Ritsumeikan University.

Francisca Gilmore-Yulee: Vice President, Investment & Platform at f7 Ventures.

Kelly Graziadei: Founding Partner & Managing Member at f7 Ventures.

Joanna Lee Shevelenko: Founding Partner & Managing Member at f7 Ventures.

Yilin Huo: Associate at S2G Investments.

Walter Robb: Operating Partner at S2G Investments.

Vikram Sharma: Operating Partner at S2G Investments.

Victoria Liu: Associate at S2G Investments.

Tonya Bakritzes: Chief Marketing Officer at S2G Investments.

Sean Nguyen: Senior Staff Data Scientist at S2G Investments.

Sumeeta Salvador: Senior Associate, Ecosystem at S2G Investments.

Rosario Bennett: Senior Associate at S2G Investments.

Sanjeev Krishnan: Managing Partner at S2G Investments.

Mya Stanislas: Impact Associate at S2G Investments.

Nick Curran: Vice President at S2G Investments.

Priyanka Duvvuru: Principal at S2G Investments.

Mohit Kalra: General Counsel at S2G Investments.

Monica Jensen: Chief Financial Officer at S2G Investments.

Mike Wise: Principal at S2G Investments.

Miles Russo: Senior Associate at S2G Investments.

Mitch Worden: Vice President, Ecosystem at S2G Investments.

Mike Gilkes: Principal at S2G Investments.

Maura Wells: Vice President, Investor Relations at S2G Investments.

Michelle Morales: Senior Associate at S2G Investments.

Mary DaSilva: Chief People Officer at S2G Investments.

Matt LaPorta: Associate at S2G Investments.

Matthew Walker: Managing Director at S2G Investments.

Mary Catherine Daniels: Executive Assistant at S2G Investments.

Marisa Sweeney: Principal at S2G Investments.

Mackenzie Longo: Executive Assistant at S2G Investments.

Larsen Mettler: Managing Director at S2G Investments.

Lisa Rosen: Fund Controller at S2G Investments.

Kevin Vincent: Chief Compliance Officer at S2G Investments.

Kevin O’Shaughnessy: Vice President, Digital Marketing at S2G Investments.

Katie Stanton: Vice President, Finance & Operations at S2G Investments.

Kevin Lo: Operating Partner at S2G Investments.

Katie Petrakos: Executive Assistant at S2G Investments.

Jusleen Huang: Associate at S2G Investments.

Kate Danaher: Managing Director at S2G Investments.

Joyce Kim: Counsel, Investments at S2G Investments.

Jinchen Zou: Senior Associate at S2G Investments.

Jessica Murphy: Principal, Director of Community at S2G Investments.

Jake Reznick: Vice President at S2G Investments.

Izzy Johnson: Senior Fund Accountant at S2G Investments.

Heather McPherson: Principal, Director of Impact at S2G Investments.

Henry Hu: Associate at S2G Investments.

Grant Leslie: Operating Partner, Government & Policy at S2G Investments.

Gokul Raghavan: Principal at S2G Investments.

Gage Wallace: Executive Assistant at S2G Investments.

Francis O’Sullivan: Managing Director at S2G Investments.

Francis Villante: Vice President at S2G Investments.

Elizabeth Andrews: Associate at S2G Investments.

Deanna Meirink: Office Coordinator at S2G Investments.

Dan Ripma: Principal at S2G Investments.

Chuck Templeton: Managing Partner at S2G Investments.

Cristina Rohr: Managing Director at S2G Investments.

Chris Marshall: Head of AI & Technology Solutions at S2G Investments.

Brian O’Connor: Managing Director & Co-Head at S2G Investments.

Caroline Hogan: Associate at S2G Investments.

Benazeer Bennardo: Executive Assistant at S2G Investments.

Bala Nagarajan: Managing Director at S2G Investments.

Bella Zimmer: Senior Fund Accountant at S2G Investments.

August O'Hern: Senior Associate at S2G Investments.

Audre Kapacinskas: Principal, Head of Ecosystem Development at S2G Investments.

Andrea Woodside: Managing Director & Co-Head at S2G Investments.

Ally Dunne: Vice President, Communications at S2G Investments.

Alexandra Miller: Executive Assistant at S2G Investments.

Aaron Rudberg: Managing Partner at S2G Investments.

Tokyo and San Carlos, California biotechnology company founded in 2016 that develops AI-powered instruments and software for single-cell analysis and sorting. Its Ghost Cytometry technology combines optical imaging, machine learning and microfluidics to distinguish and separate cells using morphology and structural information, including label-free analysis. VisionSort pairs morphological and fluorescence-based sorting for life-science research, drug discovery, disease profiling and cell-therapy development and quality control. ThinkCyte also offers MorphoScan Cloud for AI-based cell morphology analysis. Its technology originated in University of Tokyo and Osaka University research, and its instruments are used by pharmaceutical companies and academic research laboratories.

Tokyo-based clinical-stage biotechnology company founded in 2005 that discovers and develops medicines targeting SLC membrane transporters, particularly the LAT1 amino-acid transporter. Its cancer program nanvuranlat (JPH203) is a small-molecule LAT1 inhibitor being developed for biliary tract cancer and entered a global Phase III study in December 2025. Its neuroscience program JPH034 is a brain-penetrant LAT1 inhibitor being developed for multiple sclerosis, aiming to modulate inflammation and microglial activity in demyelinating lesions; Phase I began in March 2026. J-Pharma also researches additional transporter-targeting drugs and diagnostics. It listed on the Tokyo Stock Exchange Growth Market in March 2026; its medicines remain in development.

Tokyo-based deep-tech investment manager that commercializes research and technology through the Real Tech Fund platform, launched in 2015. Formerly branded Real Tech Holdings, it adopted the UntroD name in June 2024. The Japanese manager backs university and research-institute spinouts in biotechnology, energy, advanced materials, aerospace, electronics, agriculture and marine technology, providing lead investments and hands-on support for commercialization, partnerships, talent, intellectual property and international growth. Its Japanese strategy spans seed and early-stage equity funds, a crossover impact fund jointly operated with Nomura Asset Management that supports companies before and after IPO, and a venture-debt fund for early and middle-stage R&D businesses. UntroD Capital Asia is a separate Singapore group entity.

Lisa Genasci: Senior Adviser at Cibus Capital.

Justin Mundy: Senior Adviser at Cibus Capital.

Jonathan Musselwhite: Senior Adviser at Cibus Capital.

Tom Ritchie: Investment Director at Cibus Capital.

Terence Ngwerume: Consultant Investment Analyst at Cibus Capital.

Tarquin Stephenson: Consultant Venture Associate at Cibus Capital.

Zac Banducci: Consultant Investment Analyst at Cibus Capital.

Susie Harrison: Office Coordinator at Cibus Capital.

Robert Appleby: Founder and Chief Investment Officer at Cibus Capital.

Priyesh Malavia: Financial Controller at Cibus Capital.

Olga Teteruk: Consultant Senior Investment Associate at Cibus Capital.

Niamh Finch: Legal Counsel at Cibus Capital.

Mario Gao: Investment Associate at Cibus Capital.

Manuel Vilches: Senior Investment Associate at Cibus Capital.

Jeremy Alun-Jones: Chief Operating Officer at Cibus Capital.

Lucy Gray: Investor Relations Associate at Cibus Capital.

Jason Silm: Head of Agriculture at Cibus Capital.

Hugo Kelly: Investment Director at Cibus Capital.

Georgina Kuhle: Head of Impact at Cibus Capital.

Ella Exley: Investor Relations Analyst at Cibus Capital.

Fred Appleby: Head of Operations at Cibus Capital.

Damon Petrie: Consultant Investment Director at Cibus Capital.

Catherine Griggs: Cibus Representative on GP Boards at Cibus Capital.

Archie Burgess: Investment Director at Cibus Capital.

Alastair Cooper: Head of Venture at Cibus Capital.

Annie Rainsford: General Counsel at Cibus Capital.

Nolan Shah: Associate at Spero Ventures.

Stephen Wemple: Principal at Spero Ventures.

Marc Tarpenning: Venture Partner at Spero Ventures.

Sara Eshelman: General Partner at Spero Ventures.

Andrew Parker: General Partner at Spero Ventures.

Cibus Capital LLP is a London-based specialist investment advisory firm focused on food and agriculture. Founded in 2016, it advises the Cibus funds across growth and buyout investments, agricultural assets and venture capital for food-system technologies. The Cibus Enterprise strategy backs commercially emerging businesses in robotics and AI, precision agriculture, biological inputs and genetics, novel farming, nutrition and supply-chain technology. Public portfolio companies include Corvus Robotics, 4AG Robotics, Bonsai Robotics, Ecorobotix, Burro, BeeHero, EarthOptics and Phytolon. The firm reports more than $1.3 billion of assets under management and publishes a 26-person team directory including Founder and Chief Investment Officer Robert Appleby, Head of Venture Alastair Cooper, Head of Agriculture Jason Silm and COO Jeremy Alun-Jones, together with staff, consultants and senior advisers. Its 2024 sustainability report lists fund sizes of $322 million for Cibus Fund LP, $66 million for Cibus Enterprise Fund LP, $514 million for Cibus Fund II LP and $138 million for Cibus Enterprise Fund II LP. The Enterprise Fund II vehicle, managed by Cibus Investments II Limited and advised by Cibus Capital LLP, participated in Corvus Robotics' $20 million Series A-2 announced in August 2026.

Spero Ventures is an early-stage venture capital firm investing in companies that improve health, sustainability and human fulfillment. Launched in 2018, it focuses on late seed and early Series A financings, typically leading or co-leading rounds of $3 million to $10 million with initial checks of $2 million to $4 million and reserves for follow-on investment. Its AI and deep technology portfolio spans warehouse robotics, healthcare automation, drug formulation, genomics, electric vehicles, energy and agriculture. Public portfolio companies include Corvus Robotics, Persist AI, Hyro, Pickaxe, Allie Systems, Aralez Bio, Telo Trucks and Wattch. Its current public investment team consists of General Partners Shripriya Mahesh, Andrew Parker and Sara Eshelman; Venture Partner Marc Tarpenning; Principal Stephen Wemple; and Associate Nolan Shah. Spero's initial fund was announced at $100 million in March 2018. The firm announced its $125 million Spero Fund II, LP in November 2025, identifying it as a 2024-vintage fund already being deployed. Spero backed Corvus' seed financing, co-led its seed and Series A funding program described in October 2024, and participated in its $20 million Series A-2 announced in August 2026.

Robert Stevens: Independent Director at Corvus Robotics.

Arthur Chow: Principal at S2G Investments. Also a board director at Corvus Robotics.

Shripriya Mahesh: General Partner at Spero Ventures. Also a board director at Corvus Robotics.

Jackie Wu: Co-Founder & Board Director at Corvus Robotics.

Eric Andreas: Head of Finance at Corvus Robotics.

Andrew Burer: Head of Marketing at Corvus Robotics.

Parker Lusk: Head of Autonomy at Corvus Robotics.

Michael McSpedon: Chief Revenue Officer at Corvus Robotics.

Mohammed Kabir: CEO & Co-Founder at Corvus Robotics.

Dan Magnuszewski is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Eric Reich is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Rob Shavell is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Ariel Diaz is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Aaron White is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Jake Epstein is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Joe Lemay is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Brad McNamara is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

David Martirano is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Rob Biederman is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Matt Joblon is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Enrico Palmerino is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Jack Greco is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Joe Caruso is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

John Chory is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Lee Hower is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Mike Volpe is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Serguei Netessine is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Vishal Sunak is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Aaron Newman is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Andy Palmer is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Mike Salguero is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Questlove is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Rich Miner is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Shawn Gee is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Wayne Chang is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Jason Robins is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

Montinique Kniffen is operations at Impellent Ventures.

Tom Golisano is venture advisor at Impellent Ventures. The firm's public network lists an advisory affiliation; outside employment is separate.

David Brown is founder, ceo & manager at Impellent Ventures.

Phil Beauregard is manager at Impellent Ventures.

Tariq Trotter is team member at Impellent Ventures.

Impellent Ventures is an early-stage venture capital firm with offices in Rochester, New York and the Washington, DC area. It takes an operator-focused approach and backs founders across industries and geographies, particularly entrepreneurial communities outside traditional venture hubs. The firm states that it invests up to $1.5 million at preseed and seed stages. Its public portfolio includes AI businesses EnFi, Evergrowth, Lumi and Threes AI, microelectronics company Innovation Semiconductor, space technology company TRL11 and virtual sleep-care provider Ognomy Sleep. Its team page lists founder David Brown, Phil Beauregard, Tariq Trotter and operations specialist Montinique Kniffen, together with a separate network of venture advisers. Its March 2026 SEC adviser filing identifies the legal manager as Impellent Ventures, LLC and David Taylor Brown as CEO and manager, with Philip Harrison-Beauregard also a manager. Impellent led Ognomy's $1.575 million Series Seed Preferred financing announced August 2024 and participated in its $20 million Series A announced June 2026.

Singapore-based software startup developing an AI design workspace for architects, interior designers, engineers and other creative professionals. It combines sketching, rendering, image editing, video and 3D-model generation with an orchestration layer coordinating specialist AI models. Its tools let users refine architectural concepts while controlling geometry, style, materials and design intent, and explore alternative visualizations within a common workspace. Co-founded by Yiping Goh and architect Carlos Bañón, it launched its public beta in November 2025 and is expanding its design platform and international market presence.

Massachusetts-based energy technology startup founded in 2025 that develops modular solid oxide fuel-cell systems for onsite electricity generation at data centers, industrial facilities and utilities. Its technology originated at Lawrence Berkeley National Laboratory and combines materials advances with modular engineering to improve power density, efficiency, responsiveness and cost. The systems are designed to operate with natural gas, hydrogen blends and other fuels, with options for energy storage and carbon capture. Teragen is expanding engineering, manufacturing and testing to move from laboratory prototypes toward initial commercial pilots.

Singapore-based deep-tech venture capital manager operating the Real Tech Global Fund franchise within the UntroD group. It backs seed to Series B companies in Southeast Asia and other global markets developing technologies for energy transition, sustainable food and agriculture, industrial manufacturing and applied AI. The firm connects startups with Japanese corporations, financial institutions and regional industrial businesses for technical validation, manufacturing, pilots, market access and financing, alongside hands-on company-building support. The Singapore entity is UntroD Capital Asia Pte. Ltd., registration number 202205324K; the wider Real Tech Fund platform began in 2015 and adopted the UntroD brand in 2024.

Hydrogen and fuel-cell technology specialist, formerly leading electrolysis and hydrogen production programs at the US Department of Energy; technical adviser to Teragen Energy.

California-based venture capital firm backing early-stage founders building enterprise software and technologies for supply chains and the physical economy. Its themes include AI and machine learning, agentic workflows, cloud and data infrastructure, robotics, manufacturing, inventory management, procurement and logistics. NewBuild combines venture investment with industry and technology networks, strategic guidance and support for market entry and scaling. Its investment team brings prior experience at NGP Capital, NEA and Intel Capital, and works with advisers from enterprise technology and supply-chain businesses.

Atlanta-based enterprise software startup that develops an AI platform for improving product availability across manufacturers, distributors and retailers. Built on supply-chain research from Georgia Tech, its software works with existing ERP and planning systems to identify hidden demand, potential lost sales and mismatches between inventory and demand across products and locations. It uses demand forecasting, substitution analysis, digital-twin simulations and AI agents to guide or automate replenishment and inventory placement. Its Product Availability Readiness and Robust Autonomy Period metrics assess future service risk and supply-network readiness.

Osaka-based venture capital firm established in April 2021 and affiliated with the Yanmar Group. It invests in startups and manages venture funds, supporting cutting-edge technologies and innovative businesses in Japan and internationally. Its focus includes sustainable food production, clean energy and resource efficiency, labor-saving technologies and richer customer experiences, with investments spanning AI, semiconductors, robotics and quantum computing. It combines financial investment with industrial partnerships, joint research and development, and access to the Yanmar network to help startups commercialize their technologies.

Matt Jacobson: Director Of Investor Relations at Blue Heron Capital.

Nick Graziano: Principal at Blue Heron Capital.

Laura Tizard: Accounting Manager at Blue Heron Capital.

Kevin Musco: Vice President at Blue Heron Capital.

Christine Lane: Controller at Blue Heron Capital.

Jim Riley: Operating Partner at Blue Heron Capital.

Andrew Tichenor: Co-Founder & Managing Partner at Blue Heron Capital.

Tom Benedetti: Co-Founder & Managing Partner at Blue Heron Capital.

Ryan McNally: Senior Advisor at Catalyst Investors.

Lindsey Brown: Office Administrator at Catalyst Investors.

Jamie Ku: Controller at Catalyst Investors.

Jay Sidhu: Associate at Catalyst Investors.

Natalie Hallagan: Associate, Business Development at Catalyst Investors.

Jack O'Brien: Associate at Catalyst Investors.

Annie Veldman: Senior Associate at Catalyst Investors.

Killian Bubrosky: Senior Associate at Catalyst Investors.

John Buck: Principal at Catalyst Investors.

Kapil Desai: Partner at Catalyst Investors.

Sidney Kullar: Principal at Catalyst Investors.

Tyler Newton: Managing Partner at Catalyst Investors.

Brian Rich: Managing Partner & Founder at Catalyst Investors.

Karen Casalinuovo: Administrative Manager at Ognomy Sleep.

Kayla Fermoile: Partner Services Manager at Ognomy Sleep.

Marissa Otto: Digital Marketing Specialist at Ognomy Sleep.

Tannay Chandhok: Chief Technology Officer at Ognomy Sleep.

Linda Anegawa: Chief Medical Officer at Ognomy Sleep.

Pete Grandits: Chief Financial Officer at Ognomy Sleep.

June Seliber-Klein: Chief of Sleep Medicine at Ognomy Sleep.

Ken Rosenfeld: Chief Operating Officer at Ognomy Sleep.

Daniel Rifkin: Founder, President and Chief Executive Officer at Ognomy Sleep.

Ognomy Sleep is a Buffalo, New York digital health company offering virtual sleep-apnea care. Launched in 2021, its platform connects patients with sleep clinicians, arranges home sleep tests, supports diagnosis and personalized treatment, and provides follow-up care. Ognomy combines telemedicine workflows with AI-enabled automation and information exchange; clinicians remain responsible for assessment and treatment decisions. Its care network supports positive airway pressure therapy, oral appliances, weight-management care and referral for appropriate implantable neurostimulation treatment. The company also integrates wearable sleep data and collaborates with medical-device providers. Founder, President and CEO Daniel Rifkin leads the company alongside COO Ken Rosenfeld, CFO Pete Grandits, Chief of Sleep Medicine June Seliber-Klein, CMO Linda Anegawa and CTO Tannay Chandhok. Inspire Medical Systems provided seed financing in 2022. Ognomy completed a $1.575 million seed preferred financing in 2024 and announced a $20 million Series A in June 2026 led by Catalyst Investors with Blue Heron Capital participating.

Tokyo- and Kyoto-based venture capital firm founded in October 2017 that backs seed and early-stage deep-tech startups, primarily in Japan and the United States. It invests in scientific and engineering advances across climate and energy, advanced materials, robotics, space, quantum computing and frontier information technologies including AI and data science. Abies supports founders with company formation, organizational development, industrial partnerships, fundraising and international expansion. Its second flagship fund launched in August 2024 and reached an ¥8 billion final close in May 2026.

Yokohama-based quantum-computing startup founded in July 2024 from research at the Okinawa Institute of Science and Technology, with an R&D center at OIST. It develops distributed ion-trap quantum computers by combining ion-trap processors with optical microcavities and photonic interconnects. Its architecture aims to link multiple quantum processing units into scalable, fault-tolerant systems for demanding computations such as drug discovery, materials design and AI workloads. It holds an exclusive license to OIST technology and is developing prototypes and error-corrected systems; its published milestones are development goals.

Michael Carrel serves as Director at Inspire Medical Systems.

Myriam Curet serves as Director at Inspire Medical Systems. Myriam Curet is listed by Mobia Medical (formerly MicroTransponder) as Board Member. She retired as Intuitive Surgical’s executive vice president and chief medical officer in March 2026 and remains a Stanford clinical professor. Her Mobia board appointment was announced July 30, 2026.

Shelley Broader serves as Director at Inspire Medical Systems.

Shawn McCormick serves as Director at Inspire Medical Systems. Shawn McCormick is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Aldevron, Tornier, Lutonix. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Cynthia Burks serves as Director at Inspire Medical Systems.

Dana Mead Jr. serves as Director at Inspire Medical Systems. Dana G. Mead, Jr. is listed by Mobia Medical (formerly MicroTransponder) as Chairman of the Board. His healthcare operating and investing experience includes HeartFlow, BVI, Kleiner Perkins and Guidant.

Georgia Melenikiotou serves as Director at Inspire Medical Systems.

Gary Ellis serves as Director at Inspire Medical Systems.

Joe Sander serves as Senior Vice President, U.S. Sales at Inspire Medical Systems.

Andreas Henke serves as Executive Vice President, International and Managing Director at Inspire Medical Systems.

Melissa Mann serves as Chief People Officer at Inspire Medical Systems.

Bryan Phillips serves as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Inspire Medical Systems.

Jason Kelly serves as Chief Operations and Innovation Officer at Inspire Medical Systems.